Accelerating RNA vaccine development through global collaboration

The PATH RNA Cooperative is a trusted, non-competitive, manufacturer-driven group that accelerates RNA vaccine development from early research to readiness for first-in-human clinical trials. It equips selected low- and middle-income country vaccine manufacturers with hands-on expertise, shared knowledge, and collaborative resources; drives collective learning; and facilitates access to standardized approaches and strategic insights that can strengthen manufacturing and advance access to lifesaving vaccines.

Existing Members: Login

About the RNA Cooperative

The RNA Cooperative brings together emerging-market vaccine manufacturers and global nonprofit organizations to advance RNA vaccine development and manufacturing. Through innovation, capacity building, and technology transfer, the Cooperative supports development across multiple vaccine targets—laying the groundwork for sustainable, regional vaccine production with broad impact.

The RNA Cooperative embodies the spirit of collaboration by promoting shared knowledge and collective learning to achieve a common goal: expanded access to advanced vaccine technologies and a sustainable supply of lifesaving vaccines in under-served regions.

Potential of RNA technology

RNA vaccine technology is a flexible vaccine development approach able to rapidly generate safe and efficacious vaccines at large scale, but the technology has largely been inaccessible to low- and middle-income country vaccine manufacturers. During the COVID-19 pandemic, lower income countries were last in line to receive new vaccines and had vaccination rates that trailed far behind those of higher-income countries once they did—illustrating the importance of establishing RNA vaccine manufacturing to ensure equitable vaccine access at the local, regional, and global levels.

Governance and Membership

The RNA Cooperative is convened and managed by PATH and funded by the Gates Foundation. It includes two types of members:

  • Core members: Low- and middle-income country-based vaccine manufacturers developing RNA vaccine manufacturing capabilities and capacity and advancing new RNA vaccine candidates.
  • Supporting members: Organizations such as vaccine developers, academic institutions, and nonprofits providing technical expertise, platforms, and shared resources. 

Together, these members contribute to a collective vision: a more equitable, sustainable global vaccine ecosystem.

Key Focus Areas

  • Research & Design

    Lead optimization, preclinical studies, exploratory applications of artificial intelligence to optimize RNA design and development 

  • Manufacturing

    Raw material sourcing, process development, GMP-compliant production 

  • Clinical & Regulatory

    Trial readiness, regulatory navigation, documentation harmonization